Disappointing Prostate Cancer Phase III Results for Cabozantinib.
Exelixis, the biotechnology firm developing the metastatic medullary thyroid cancer drug, cabozantinib, in the treatment of a variety of cancers, recently announced disappointing Phase III clinical trial results for the use of cabozantinib in the treatment of metastatic, hormone-resistant (refractory) prostate cancer. The drug continues to be clinically evaluated in metastatic renal cell and advanced hepatocellular carcinomas.
This entry was posted in 2014
. Bookmark the permalink